What is Normunity?
Normunity is a biotechnology company dedicated to creating novel anti-cancer therapies. Its scientific approach targets mechanisms that influence tumor growth and evade immune surveillance, aiming to overcome tumor clearance resistance. The company is building a diverse pipeline that includes therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. Normunity's lead program, NRM823, is a T cell engager designed for multiple solid tumors with tumor-specific targeting, slated for clinical entry in 2025. The company operates across Boston, MA, and New Haven, CT, with its digital presence at www.normunity.com.
How much funding has Normunity raised?
Normunity has raised a total of $140M across 2 funding rounds:
Series A
$65M
Series B
$75M
Series A (2022): $65M with participation from Osage University Partners, investorCanaan Ventures, Taiho Ventures, and Sanofi Ventures
Series B (2025): $75M led by Samsara BioCapital, Canaan Partners, Pfizer, Taiho Ventures, Regeneron Ventures, Sanofi Ventures, Enavate Sciences, Connecticut Innovations, Osage Venture Partners, and YK
Key Investors in Normunity
Osage University Partners
Osage University Partners is a venture capital firm that exclusively invests in innovative startups emerging from leading universities and research institutions worldwide, targeting a variety of sectors including therapeutics and diagnostics.
Taiho Ventures
Taiho Ventures, LLC focuses on investing in the global biotech venture community, aiming to create significant value and provide innovative scientific advancements for Taiho Pharmaceutical Co., Ltd.
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi, particularly in oncology and immunology.
What's next for Normunity?
The recent major strategic investment of $75M positions Normunity for accelerated development and potential commercialization of its anti-cancer therapies. This capital infusion, contributing to the overall $140M, is expected to fuel the advancement of its lead program, NRM823, into clinical trials and further expand its pipeline of novel biologics. The company's focus on targeting fundamental mechanisms of tumor growth and immune evasion suggests a strategy aimed at addressing significant unmet needs in oncology, potentially leading to breakthrough treatments. Future growth will likely involve strategic partnerships, further clinical development, and scaling manufacturing capabilities to support its expanding therapeutic offerings.
See full Normunity company page
